Search Results
Your search for can matches 13479 pages
Showing 6451 - 65002018 Quality Care: Opioid Deaths Are 10 Times Less Likely to Occur in Patients With Cancer Compared to the General Population
According to the U.S. Department of Health and Human Services, in 2016, over 42,000 Americans died from opioid overdose, making the epidemic a top public health concern. Although opioids are commonly used for cancer-associated pain, the risks for overdose in patients with cancer were unknown. A...
New Benchmarking Tool for Measuring Implementation of Integrated Practice Units
New research by Wind et al in JNCCN—Journal of the National Comprehensive Cancer Network explores a new approach for benchmarking cancer centers based on how successfully their organizational structures allow them to implement integrated practice units (IPUs). These IPUs are defined ...
ASCO Endorses CAP Guideline on HPV Testing in Head and Neck Carcinoma
As reported in the Journal of Clinical Oncology by Carole Fakhry, MD, MPH, of Johns Hopkins School of Medicine, and colleagues, ASCO has endorsed the 2018 College of American Pathologists (CAP) guideline on human papillomavirus (HPV) testing in head and neck carcinoma. The endorsement was based on...
Estimated Medicare Cost for Prostate Cancer Care in Older Men
Although national guidelines recommend against prostate cancer screening in men age 70 and older, researchers from the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center estimate that screening for and treating prostate cancer in men in this age group costs Medicare more than ...
ASCO Endorses AUA/ASTRO/SUO Guideline on Clinically Localized Prostate Cancer
As reported in the Journal of Clinical Oncology by Justin E. Bekelman, MD, of the University of Pennsylvania Perelman School of Medicine, and colleagues, ASCO has endorsed the 2017 American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic...
ASCO Journals Editorial Fellowship
Scientific journals are a cornerstone of medical knowledge, delivering information about the latest research discoveries to the medical professionals who will put them into practice. Once a manuscript is submitted, a journal editor guides it through peer review, extensive editing, and publication....
ASCO and Friends of Cancer Research Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation
On August 8, ASCO and Friends of Cancer Research (Friends) submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration...
Newly Updated! ASCO Answers Guide to Small Cell Lung Cancer for Your Patients
Fully updated and now with 8th Edition AJCC staging information, this updated guide is designed for people newly diagnosed with small cell lung cancer to help them get organized and learn more about their diagnosis, treatment options, side effects, support options, follow-up care, and more. It...
Meet Your ASCO President-Elect, Dr. Howard A. ‘Skip’ Burris
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time ASCO member and volunteer, began his role as ASCO President-Elect in June 2018. An ASCO member for nearly 30 years, Dr. Burris’ service to the Society is extensive. His volunteer roles include member of the ASCO Board of Directors and...
Wally Curran, MD, FACR, FASCO, Reflects on a Career in Academic Oncology
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. Find him on Twitter @jamecancerdoc. For this installment of the Living a Full Life series, guest editor, Jame Abraham, MD,...
Actively Recruiting Clinical Trials Focused on Gynecologic Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on gynecologic cancers—cervical, vaginal, uterine, ovarian, and vulvar cancers. These trials are studying chemoradiotherapy combination treatments, cancer vaccines, intraperitoneal ...
Are E-Cigarettes a Dangerous Alternative to Traditional Cigarettes?
Several studies published earlier this year present preliminary but compelling evidence that electronic cigarettes, also known as e-cigarettes, which deliver nicotine through aerosols without burning tobacco, may pose serious health consequences to users, including cardiovascular disease and...
CAR T-Cell Therapy for CLL
A pair of new studies from researchers at the Abramson Cancer Center of the University of Pennsylvania are shedding light on why patients with advanced chronic lymphocytic leukemia (CLL) respond or do not respond to chimeric antigen receptor (CAR) T-cell therapy. Although CAR T-cell therapy is...
Maintenance Therapy for Metastatic Colorectal Cancer: Benefit Seen With Panitumumab Combination
Although the optimal approach to maintenance is not definitive in patients with metastatic colorectal cancer who have undergone chemotherapy-based induction with anti–endothelial growth factor receptor (EGFR) agents, the phase II VALENTINO trial showed that anti-EGFR maintenance therapy with...
Pembrolizumab for Advanced Cervical Cancer Progressing During or After Chemotherapy
In June 2018, pembrolizumab (Keytruda) was approved for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express programmed cell death ligand 1 (PD-L1; combined positive score [CPS] ≥ 1), as determined by a U.S....
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On June 13, 2018, pembrolizumab (Keytruda) was granted...
Durable Response With Venetoclax and Azacitidine in Elderly Patients With AML
In elderly patients with untreated acute myeloid leukemia (AML), venetoclax (Venclexta), given at a 400-mg dose, with an azacitidine backbone led to durable responses with a tolerable safety profile, according to data from a phase Ib dose-escalation and -expansion study. Response rates were high...
Update on Clinical Trials of Novel Therapies
Long-term follow-up data on axicabtagene ciloleucel (Yescarta) in lymphoma, potential partners for nivolumab (Opdivo) in solid tumors, and a targeted agent for RET-altered cancers were featured during the developmental therapeutics program at the 2018 ASCO Annual Meeting. At the Best of ASCO...
An Invitation to Be Quiet No Longer
My male colleagues sometimes broach the topic of #MeToo or sexual harassment in medicine by saying how uncomfortable it makes them. Ah, yes. How uncomfortable the sexual harassment I have faced for years makes you. I casually bring up microaggressions—subtle verbal or nonverbal slights against...
Risk of Second HPV-Associated Cancer Among Survivors of HPV-Associated Cancers
A retrospective study led by researchers at Baylor College of Medicine and The University of Texas Health Science Center at Houston (UTHealth) School of Public Health found that survivors of human papillomavirus (HPV)-associated cancers have a high incidence of developing second ...
Cabozantinib in Second-Line Treatment of Advanced Hepatocellular Carcinoma
Compared with placebo, cabozantinib (Cabometyx) significantly improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who were previously treated with sorafenib (Nexavar), with no new safety signals, according to data from the phase III CELESTIAL ...
FDA Takes New Steps to Address Youth E-Cigarette Use
The U.S. Food and Drug Administration (FDA) has announced a series of critical and historic enforcement actions related to the sale and marketing of e-cigarettes to children. In the largest coordinated enforcement effort in the its history, the agency issued more than 1,300 warning...
Mismatch Repair Mutations and Immunotherapy in Prostate Cancer
A group of men with especially aggressive prostate cancer may respond unusually well to immunotherapy, according to a study published by Rodrigues et al in the Journal of Clinical Investigation. The research offers the possibility of effective treatment, with clinical trials already underway. An...
Presurgical CT Imaging of CD117-Positive Kidney Tumors
A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography (CT) imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine—before surgery—whether the tumor is benign or malignant. Their findings...
Study Finds Hispanic Pediatric Patients at Increased Risk of Methotrexate Neurotoxicity During Treatment for ALL
Case studies have reported a high prevalence of methotrexate subacute neurotoxicity among Hispanic adolescents with acute lymphoblastic leukemia (ALL), suggesting sensitivity to methotrexate therapy may differ by race and ethnicity. Now, a prospective study in pediatric patients with ALL has found...
Lasker Foundation Announces 2018 Lasker Awards for Basic and Clinical Medical Research and Special Achievement
The Albert and Mary Lasker Foundation today announced the winners of its 2018 Lasker Awards: C. David Allis, PhD, of Rockefeller University and Michael Grunstein, PhD, of the University of California, Los Angeles, will receive the Albert Lasker Basic Medical Research...
ASCO Answers Palliative Care: A Resource for Your Patients
THE ASCO ANSWERS Palliative Care booklet shares how palliative care or supportive care is used to manage symptoms and side effects; help with practical concerns; address spiritual questions; and support caregivers, family, and friends. Your patients will find: Practical advice on how to access...
Applying for a Conquer Cancer Research Grant: Tips From Past YIA and CDA Recipients
Research grants are vital to the success of academic research and researchers apply for these grants at all stages of their career. This makes writing stand-out grant applications an incredibly valuable skill for clinical investigators—and an intimidating task for first-time grant applicants....
Becoming a Leader in Oncology With ASCO’s Leadership Development Program
ASCO offers a portfolio of prestigious leadership training opportunities for those who are ready to take the next step in their careers. This includes the Leadership Development Program (LDP), a program that began in 2009 and was created to teach mid-career oncologists leadership skills and help...
Lung Cancer Expert Leora Horn, MD, Recalls Her Journey to a Career in Oncology and a Home in Nashville
The tumultuous history of modern South Africa has numerous stories that lie beneath the surface of the sociopolitical headlines, such as the story of lung cancer expert Leora Horn, MD. “I was born and reared in Johannesburg, South Africa, a second-generation African family. In 1987, because of the...
Georgetown Launches Open Access Brain Cancer Biomedical Database
THE GEORGETOWN Lombardi Comprehensive Cancer Center has developed and released a cache of brain cancer biomedical data and made them freely available to researchers worldwide. The database, referred to as REMBRANDT (Repository for Molecular Brain Neoplasia Data), contains information on 671 adult...
Male Breast Cancer: An Understudied Malignancy
Male breast cancer is a rare and understudied malignancy when compared with female breast cancer, with conflicting literature on survival outcomes in men and women. The ASCO Post spoke recently with breast cancer expert Sharon Giordano, MD, MPH, FASCO, Professor at The University of Texas MD...
Expanding the Use of Provider Orders for Life-Sustaining Treatment for Patients With Advanced Cancer
Patients with advanced cancer often get more aggressive treatment than they want because too few oncologists elicit their end-of-life treatment preferences.1,2 In response to this problem, leading associations, including ASCO3,4 and the Institute of Medicine,5 have called for more advance care...
Ana María López, MD, MPH, Becomes Chief of Cancer Services at Sidney Kimmel
ANA MARÍA LÓPEZ, MD, MPH, has joined the Sidney Kimmel Cancer Center (Sidney Kimmel), Jefferson Health, as Vice Chair of Medical Oncology and Chief of Cancer Services. Dr. López brings her expertise in breast and gynecologic cancers, integrative medicine, telehealth, and cancer disparities with...
Challenges of Managing Older Patients With Diffuse Large B-Cell Lymphoma
As the population continues to age, the interplay between aging and cancer increasingly shows cancer to be a disease of older people. By the year 2030, there will be an increased incidence of non-Hodgkin lymphoma (NHL) in older individuals.1 The median age of patients diagnosed with diffuse large...
Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?
USING THE National Cancer Database, Bhatt et al1 recently reported that of the 61,775 adults with acute myeloid leukemia (AML), those who received chemotherapy from 2003 to 2011 lived longer than those who, in those same years, did not; the study is reviewed in this issue of The ASCO Post....
Expert Point of View: Ian Olver, MD, PhD
COMMENTING ON the importance of this topic at a press conference during the 2018 Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, Ian Olver, MD, PhD, Immediate Past President of MASCC and Director of the University of...
No Improvement in Survival Reported With Epacadostat Plus Pembrolizumab in Advanced Melanoma
IN PATIENTS with unresectable or metastatic melanoma, adding epacadostat to pembrolizumab (Keytruda) did not result in greater clinical benefit over pembrolizumab alone, according to data from the phase III ECHO-301/KEYNOTE-252 study. These results were originally presented at the 2018 ASCO Annual...
Recent Drug Approvals and Revisions in Prescribing Information
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) issued the following approvals and prescribing information revisions in August 2018. Lenvatinib Approved for Unresectable Hepatocellular Carcinoma THE FDA approved lenvatinib (Lenvima) for the first-line treatment of patients with unresectable...
Clarifying the Complexity of Genomic Testing in Non-Hodgkin Lymphoma
AS MORE is learned about the genomic landscape in non-Hodgkin lymphoma, clinicians are grappling with how to apply this information in the clinic. At the 2018 Pan Pacific Lymphoma Conference, Andrew D. Zelenetz, MD, PhD, helped them understand this emerging area.1 Dr. Zelenetz is Professor of...
Relapsed or Refractory Hodgkin Lymphoma: Optimizing Salvage Therapy
As novel therapies come on board for treating relapsed or refractory Hodgkin lymphoma, the field is advancing toward more personalized therapy. The goal, even in the advanced-disease setting, is to increase the chances of complete response and negative positron-emission tomography (PET), while...
Proteomics May Be Used to Predict Treatment Outcomes in Triple-Negative Breast Cancer
In triple-negative breast cancer, researchers have so far been unable to identify markers that can classify patients by prognosis or probability of responding to different treatments. In a study published by Zagorac et al in Nature Communications, researchers from the Spanish National Cancer...
Over 130 Buildings and Landmarks in the United States and Canada to Be Illuminated in Support of Stand Up To Cancer's 6th Live Telecast
More than 130 iconic buildings and landmarks across the United States and Canada will be illuminated in a show of support for the 6th biennial Stand Up To Cancer (SU2C) “roadblock” telecast airing in both countries on Friday, September 7 (8:00–9:00 PM ...
Treating Nonmetastatic Castration-Resistant Prostate Cancer: Implications of the PROSPER Trial
A MAN in his early 70s sits in our office. His general health is good, and he is feeling well. Yet he is deeply worried. Four years ago, when his prostate-specific antigen (PSA) level rapidly increased after radical prostatectomy and subsequent radiation therapy, he was started on...
Prediction of Survival and Disease Control in HPV-Negative Head and Neck Cancer Using Molecular Markers
A new method may predict the course of human papillomavirus (HPV)-negative head and neck cancer after radiochemotherapy. According to findings published by Hess et al in Clinical Cancer Research, five microRNAs (miRNAs) may be able to provide the decisive data. Squamous cell carcinomas of the head ...
Genetic Forecasting May Predict Response to Cetuximab in Colorectal Cancer
Blood tests could predict how long it takes until colorectal cancer becomes resistant to treatment based on the same principle used in forecasting the weather, a new study by Khan et al in Cancer Discovery has found. The liquid biopsies could also predict patients that are unlikely to initially...
NCCN Publishes New Guidelines for Rare Cancers Associated With Pregnancy
The National Comprehensive Cancer Network® (NCCN®) has released new treatment guidelines for a group of rare cancers that impact women during pregnancy. Gestational trophoblastic neoplasia, also known as gestational trophoblastic disease, may occur when tumors develop in the cells that would...
A Daughter Struggles Through Her Father’s Battle With Cancer
BOOKMARK Title: White Hot Grief Parade: A Memoir Author: Alexandra Silber Publisher: Pegasus Books Publication date: July 2018 Price: $25.95, hardcover; 288 pages The sudden death of a loved one produces a different type of trauma for family and friends than the protracted fading away of cancer. ...
Love in the Time of Cancer
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment
Subsolid nodules can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance. Conservative management of subsolid nodules may reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from...
